Recent advances in MS-based proteomics have significantly increased the quality and scope of biological information that can be derived from human samples. These technological advances have made current workflows increasingly applicable in biomedical and clinical contexts.
In this RT, world-wide experts in the field will illustrate the latest advances and applications in clinical proteomics and modification-proteomics applied to different diseases and will discuss the current challenges and opportunities towards establishing proteomics within the multi-omics workflows that are transforming personalized medicine.
Proponent and Chair Person
European Institute of Oncology (IEO), Milan, IT
Jennifer Van Eyk "Use of MS to Empower Personalized Medicine"
Advanced Clinical Biosystems Institute, Cedars Sinai, Los Angeles, US
Matthias Mann "Ultra-high Sensitivity Proteomics for Single Cell and Tissue Proteomics"
Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, DE
Bernhard Küster "Adding a Proteomic Component to Molecular Tumor Boards"
Technical University of Münich (TUM), Proteomics and Bioanalytics, Freising, DE